Viemed Healthcare, Inc. reported fourth‑quarter 2025 results that set new company records, with net revenues of $76.2 million—an increase of $15.5 million, or 26%, over the comparable quarter of 2024. The company’s earnings per share of $0.14 beat the consensus estimate of $0.12, a $0.02 or 16.7% beat, while the revenue miss of $1.6 million (1.8% below the $77.8 million estimate) underscored a modest shortfall in top‑line growth.
The revenue growth was driven by a 63% jump in equipment sales, largely from the acquisition of Lehan’s Medical Equipment and strong demand in sleep resupply and maternal‑health segments. Service revenue rose 24% to $4.8 million, led by a 30% increase in healthcare‑staffing contracts. Ventilator rentals grew 10% to $12.2 million, while other home‑medical equipment rentals increased 20% to $9.7 million, reflecting a shift toward higher‑margin service and non‑ventilator products.
Management guided for 2026 net revenue of $310 million to $320 million and adjusted EBITDA of $65 million to $69 million—midpoints that fall below the analyst consensus of $335.9 million for revenue and $70 million for EBITDA. The conservative outlook signals caution amid headwinds from the updated National Coverage Determination, which has limited ventilator patient growth, and a 100% success rate on Medicare Advantage appeals that required additional compliance investment.
The Board authorized a share‑repurchase program effective through March 2027, allowing Viemed to buy back up to 1,930,131 common shares, roughly 5% of the outstanding shares as of March 4 2026. This is the company’s fourth buyback program; prior programs totaled $26.3 million and repurchased about 4.5 million shares, while a June 2025 program authorized 1,976,441 shares and was completed by September 23 2025 for $13.2 million.
Investors reacted negatively to the earnings release, with the stock falling in after‑hours trading. The decline was driven primarily by the revenue miss and the below‑consensus 2026 guidance, which outweighed the EPS beat. The market’s focus on sustained top‑line growth and forward guidance highlights the importance of revenue momentum to investor confidence.
Viemed’s results illustrate a company in transition: diversification beyond ventilator rentals into sleep, resupply, and maternal‑health segments is reducing reliance on legacy products, while the acquisition of Lehan’s Medical Equipment expands its product portfolio. The company’s gross margin of just under 58% is expected to remain stable as the mix shifts toward higher‑margin services. However, the NCD headwinds and cautious guidance suggest management is mindful of potential demand slowdowns, even as it continues to invest in growth and return capital to shareholders through the new buyback program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.